<DOC>
	<DOC>NCT01756248</DOC>
	<brief_summary>This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD). The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice. A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.</brief_summary>
	<brief_title>EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Patients who received EYLEA for AMD Patients who have already received EYLEA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EYLEA</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
</DOC>